ABUS vs. QTUM

Last updated Apr 2, 2026

Compare and contrast key facts about Arbutus Biopharma Corporation (ABUS) and Defiance Quantum ETF (QTUM).

QTUM is a passively managed fund by Defiance that tracks the performance of the BlueStar Machine Learning and Quantum Computing Index. It was launched on Sep 5, 2018.

Performance

ABUS vs. QTUM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arbutus Biopharma Corporation (ABUS) and Defiance Quantum ETF (QTUM). The values are adjusted to include any dividend payments, if applicable.

ABUS vs. QTUM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
ABUS Arbutus Biopharma Corporation	-6.03%	47.09%	30.80%	7.30%	-40.10%	9.58%	27.70%	-27.42%	-65.18%
QTUM Defiance Quantum ETF	-0.14%	36.65%	50.54%	39.86%	-28.80%	35.18%	42.05%	47.99%	-19.02%

Returns By Period

In the year-to-date period, ABUS achieves a -6.03% return, which is significantly lower than QTUM's -0.14% return.

ABUS

• 1D: 0.44%
• 1M: -3.21%
• YTD: -6.03%
• 6M: -1.53%
• 1Y: 29.89%
• 3Y*: 14.26%
• 5Y*: 5.67%
• 10Y*: 0.81%

QTUM

• 1D: 1.85%
• 1M: -6.11%
• YTD: -0.14%
• 6M: 3.08%
• 1Y: 47.58%
• 3Y*: 34.18%
• 5Y*: 18.84%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ABUS vs. QTUM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABUS

ABUS Risk / Return Rank: 61
ABUS Sharpe Ratio Rank: 62
ABUS Sortino Ratio Rank: 57
ABUS Omega Ratio Rank: 56
ABUS Calmar Ratio Rank: 64
ABUS Martin Ratio Rank: 66

QTUM

QTUM Risk / Return Rank: 84
QTUM Sharpe Ratio Rank: 81
QTUM Sortino Ratio Rank: 83
QTUM Omega Ratio Rank: 77
QTUM Calmar Ratio Rank: 91
QTUM Martin Ratio Rank: 88

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ABUS vs. QTUM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and Defiance Quantum ETF (QTUM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ABUS	QTUM	Difference
Sharpe ratio Return per unit of total volatility	0.62	1.61	-0.99
Sortino ratio Return per unit of downside risk	1.11	2.24	-1.13
Omega ratio Gain probability vs. loss probability	1.14	1.30	-0.16
Calmar ratio Return relative to maximum drawdown	1.14	3.16	-2.02
Martin ratio Return relative to average drawdown	2.99	11.08	-8.09
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ABUS vs. QTUM - Sharpe Ratio Comparison

The current ABUS Sharpe Ratio is 0.62, which is lower than the QTUM Sharpe Ratio of 1.61. The chart below compares the historical Sharpe Ratios of ABUS and QTUM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ABUS	QTUM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.62	1.61	-0.99
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.10	0.72	-0.62
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.01	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	0.84	-0.93

Correlation

The correlation between ABUS and QTUM is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ABUS vs. QTUM - Dividend Comparison

ABUS has not paid dividends to shareholders, while QTUM's dividend yield for the trailing twelve months is around 1.07%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018
ABUS Arbutus Biopharma Corporation	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
QTUM Defiance Quantum ETF	1.07%	1.01%	0.61%	0.81%	1.46%	0.48%	0.42%	0.61%	0.21%

Drawdowns

ABUS vs. QTUM - Drawdown Comparison

The maximum ABUS drawdown since its inception was -92.96%, which is greater than QTUM's maximum drawdown of -38.45%. Use the drawdown chart below to compare losses from any high point for ABUS and QTUM.

Drawdown Indicators

	ABUS	QTUM	Difference
Max Drawdown Largest peak-to-trough decline	-92.96%	-38.45%	-54.51%
Max Drawdown (1Y) Largest decline over 1 year	-25.86%	-15.26%	-10.60%
Max Drawdown (5Y) Largest decline over 5 years	-63.42%	-38.45%	-24.97%
Max Drawdown (10Y) Largest decline over 10 years	-92.96%	—	—
Current Drawdown Current decline from peak	-63.40%	-9.34%	-54.06%
Average Drawdown Average peak-to-trough decline	-68.84%	-8.40%	-60.44%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.88%	4.36%	+5.52%

Volatility

ABUS vs. QTUM - Volatility Comparison

Arbutus Biopharma Corporation (ABUS) has a higher volatility of 15.46% compared to Defiance Quantum ETF (QTUM) at 9.77%. This indicates that ABUS's price experiences larger fluctuations and is considered to be riskier than QTUM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ABUS	QTUM	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.46%	9.77%	+5.69%
Volatility (6M) Calculated over the trailing 6-month period	36.71%	20.87%	+15.84%
Volatility (1Y) Calculated over the trailing 1-year period	48.44%	29.70%	+18.74%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	55.56%	26.21%	+29.35%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	85.71%	27.05%	+58.66%